Replies to post #696322 on BB's Stock Haven

[december]

Viropro, Inc. Rated 'Outperform,' Target $2.60 by Beacon Equity Research

DALLAS, Jul 27, 2006 (BUSINESS WIRE) -- Viropro, Inc. (OTCBB:VPRO) has been rated "Outperform" with a target price of $2.60 by Beacon Equity Senior Research Analyst, Kris Goldcross, CFA.
The full report is available at http://www.BeaconEquityResearch.com
In the report Mr. Goldcross writes, "Viropro specializes in marketing its expertise in technology transfer for the industrial production of therapeutic proteins. The company's primary objective is to make therapeutic proteins (whose patents have expired) readily available to pharmaceutical partners located in emerging regions of the globe with unmet medical needs, including South America, Asia and Africa. The company is also focusing on the development and marketing of therapeutic vaccines against cancer or chronic infections such as AIDS."
"Given the company's exposure to the biotechnology industry, we have compared Viropro to similar publicly trading companies that are engaged in the production of therapeutic drugs. These include Lexicon Genectics, Inc. (Nasdaq:LEXG); Pharmaceutical Product Development, Inc. (Nasdaq:PPDI); Gilead Sciences, Ltd. (Nasdaq:GILD); Genzyme Corporation (Nasdaq:GENZ) and PDL BioPharma, Inc. (Nasdaq:PDLI)."
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of Viropro, Inc. (VPRO). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon has directly been compensated six-thousand dollars directly by Viropro for enrollment in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
Anyone interested in receiving alerts regarding Viropro, Inc. research should email [e-mail] with "VPRO" in the subject line.
SOURCE: Viropro, Inc.
CONTACT: Beacon Equity Research Jeff Bishop, 469-252-3035 [e-mail] www.BeaconEquityResearch.com or Viropro Inc. Daniel Benchetrit, 514-731-VPRO (8776) - Extension 225 [e-mail]
Copyright Business Wire 2006

[i_like_bb_stock]

UAMA chart not bad needs volume